BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Biomanufacturing strategy at BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

34 organizations at BIO-Europe 2026 present work in biomanufacturing strategy: 21 drug developers, 9 service providers, 3 academic, government and non-profit bodies and 1 investor. Between them they bring 56 presentations to the program. Most represented: Bayer (6 on the program), Boehringer Ingelheim (5 on the program), Johnson & Johnson (4 on the program). As of Nov 10, 2026.

All 473 organizations at BIO-Europe 2026 →

Format
Top represented
Showing 1–12 of 34 organizations
OrganizationBIO-Europe 2026 Attendance
Bayer
Leverkusen, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Life sciences company with pharmaceuticals, consumer health and crop science divisions.
Talk
Tue Nov 10
09:00–09:30
An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation
How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare.
Panel
Tue Nov 10
15:00–15:25
Inside the Incubator: What It Really Takes to Build a Biotech Company Today
What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners.
with Phinomics
Panel
Tue Nov 10
16:30–16:55
The Role of Innovation in Biopharma Growth
How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples.
Panel
Wed Nov 11
10:00–10:45
AI Regulations: Driving Innovation While Navigating Compliance
What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation.
with European Medicines Agency
Panel
Wed Nov 11
11:00–12:00
Collaborative Innovation in CDMO Partnerships
How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle.
with Eleva, Evotec
Boehringer Ingelheim
Ingelheim am Rhein, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Family-owned pharmaceutical company developing human and animal health medicines.
Panel
Mon Nov 9
13:00–13:45
Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem
How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery.
with MichBio, XGEN Venture, Merck KGaA
Talk
Tue Nov 10
13:00–14:00
Biologics Manufacturing Excellence
How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently.
with Immatics, ValiRx, Pfizer +1 more
Talk
Tue Nov 10
09:30–09:45
Pharma Presentation: Boehringer Ingelheim
Boehringer Ingelheim, independent since 1885, and its research on human and animal medicines for diseases that lack good treatments.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, AAVantgarde Bio, Inveready +1 more
Panel
Wed Nov 11
10:00–10:45
Most Favoured Nations: A Game-Changer for Biotech Dealmaker?
How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans.
with EUCOPE, Bristol Myers Squibb
Johnson & Johnson
New Brunswick, NJ
◆Platinum Sponsor · Johnson & Johnson Innovation
Large pharmaPlatinum sponsor
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups.
Panel
Mon Nov 9
16:15–17:00
Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?
What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies.
with 59 North Communications, Gateway Factory, CSL Behring +1 more
Panel
Tue Nov 10
10:00–10:25
Regulatory Updates for Orphan and Pediatric Medicines
How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, Boehringer Ingelheim, AAVantgarde Bio +1 more
Panel
Wed Nov 11
12:00–12:45
What's Next for Biomanufacturing Strategies?
Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up.
with Resolution Therapeutics, Valneva, IDT Biologika
Novo Nordisk
Bagsværd, Denmark
◆Gold Sponsor
Large pharmaGold sponsor
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases.
Panel
Mon Nov 9
11:15–12:00
Unlocking Pharma’s Productivity Potential
Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive.
with Norstella, M Ventures, Blackstone Life Sciences +1 more
Business of Biotech
Panel
Tue Nov 10
15:30–15:55
Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships
How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas.
Panel
Tue Nov 10
10:00–10:45
Cardiometabolic innovations beyond GLP-1 – Where are we now?
Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going.
with LifeArc, Atrogi, IsomAb +2 more
Panel
Tue Nov 10
15:00–15:45
Longevity – Are we getting younger?
What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape.
with Longevity.Technology, Asabys Partners, Chrysea +1 more
Miltenyi Biomedicine
Bergisch Gladbach, Germany
Biotech
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease.
Panel
Tue Nov 10
10:00–10:45
Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making
How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner.
with IGES Institut, Krystal Biotech, EFPIA +1 more
Panel
Tue Nov 10
09:30–09:55
From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients
Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials.
Talk
Wed Nov 11
09:30–09:55
Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies
How cell therapies built for cancer are moving into autoimmune disease, and how trial endpoints, risk expectations and teams must change.
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases.
Panel
Tue Nov 10
16:00–16:45
Unlocking Clinical Trial Systems
How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely.
with R Kupiec Consulting, Parexel, Merck KGaA
Panel
Wed Nov 11
09:00–09:30
Sustainability & Innovation: Transforming Biopharma Partnerships for a Greener Future
How drug companies, smaller firms and suppliers can team up to cut supply chain carbon emissions and bring greener technologies to industrial scale.
Evotec
Hamburg, Germany
◆Platinum Sponsor
CDMO & CROPlatinum sponsor
Drug discovery and development partner providing research services and biologics development and manufacturing to pharma and biotech.
Panel
Tue Nov 10
17:00–17:45
Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World
How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world.
with Handelsblatt, Circio, Angelini Ventures +1 more
Business of BiotechBiomanufacturing Strategy
Panel
Wed Nov 11
11:00–12:00
Collaborative Innovation in CDMO Partnerships
How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle.
with Eleva, Bayer
Lonza
Basel, Switzerland
◆Platinum Sponsor
CDMO & CROPlatinum sponsor
Contract development and manufacturing organization for biologics, small molecules, and cell and gene therapies.
Talk
Mon Nov 9
15:30–15:55
Beyond the Race to IND: Balancing Speed, Risk and Future Value
When racing to first human trials pays off for a biotech, and when that speed creates risks for manufacturing and growth later on.
Panel
Tue Nov 10
15:00–15:25
Scaling Biologics Manufacturing in a Changing World: How Biopharma is Rethinking Launches, Partnerships and Resilience
How political uncertainty and trade shifts are changing how drug companies pick outside manufacturers, including whether to produce closer to home.
with BioSpace
Pfizer
New York, NY
◇Silver Sponsor
Large pharmaSilver sponsor
Pharmaceutical company developing and marketing medicines and vaccines across oncology, vaccines, internal medicine and other areas.
Talk
Tue Nov 10
13:00–14:00
Biologics Manufacturing Excellence
How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently.
with Immatics, Boehringer Ingelheim, ValiRx +1 more
Keynote
Tue Nov 10
13:00–13:45
Keynote: Day in the Life of an experienced dealmaker
Experienced drug-company dealmakers and venture investors share how they see the life sciences industry today and how biotechs can find their way.
with EVOLUTION Life Science Partners, ESC Advisors, Eli Lilly
AV
Investors & finance
Corporate venture capital arm of Angelini Industries, investing in biotech, medtech and digital health companies.
Keynote
Mon Nov 9
12:00–13:00
Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition, Argenx and Tubulis
How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets.
with Evaluate, Andera Partners, Tubulis +1 more
Ecosystem InnovationBusiness of Biotech
Panel
Tue Nov 10
17:00–17:45
Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World
How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world.
with Handelsblatt, Circio, Evotec +1 more
Business of BiotechBiomanufacturing Strategy
Consulting, legal & services
News site and job board covering the biotech, pharmaceutical and clinical research industries.
Panel
Tue Nov 10
15:00–15:25
Scaling Biologics Manufacturing in a Changing World: How Biopharma is Rethinking Launches, Partnerships and Resilience
How political uncertainty and trade shifts are changing how drug companies pick outside manufacturers, including whether to produce closer to home.
with Lonza
Chair
Wed Nov 11
08:55–09:00
Chairperson Opening Remarks
Biomanufacturing Strategy
◆Platinum Sponsor
Gov, delegations & associationsPlatinum sponsor
Health innovation cluster of Wallonia, Belgium, connecting biotech and medtech companies, universities and research centres.
Talk
Wed Nov 11
10:30–11:00
From Innovation to Scalable Manufacturing: Closing the Gap
Biotechs, researchers and contract manufacturers discuss what it takes to scale a new therapy into a product made reliably under strict quality rules.
with Superbranche, Cellistic, Fraunhofer IZI

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in biomanufacturing strategy

Tell us what you sell and we’ll find the people at organizations working on biomanufacturing strategy most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse BIO-Europe 2026 by

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction